These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 8683680

  • 1. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
    Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL.
    J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
    [Abstract] [Full Text] [Related]

  • 2. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E.
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
    Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS.
    J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
    [Abstract] [Full Text] [Related]

  • 4. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.
    Cancer Detect Prev; 2000 Feb; 24(4):364-8. PubMed ID: 11059567
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S, Biri H, Sinik Z, Küpeli B, Alkibay T, Bozkirli I.
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [Abstract] [Full Text] [Related]

  • 6. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
    Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I.
    Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
    [Abstract] [Full Text] [Related]

  • 7. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
    Paoluzzi M, Cuttano MG, Mugnaini P, Salsano F, Giannotti P.
    Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
    Chahal R, Darshane A, Browning AJ, Sundaram SK.
    Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF.
    Ann Clin Lab Sci; 2006 Oct; 36(1):31-8. PubMed ID: 16501234
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 14. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A.
    Anticancer Res; 1999 Mar; 19(4A):2621-3. PubMed ID: 10470205
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.